Bronchipret TP film-coated tablets blister pack of 20 pcs.

Pharmacodynamics. The herbal components that make up the Bronchipret TP preparation have secretolytic and antispasmodic properties.

Saponins from primrose roots exhibit a secretolytic effect, which is achieved mainly through a reflex mechanism due to irritation of the sensitive nerve endings of the vagus nerve of the digestive tract.

Essential oils and flavonoids of thyme herb have bronchospasmolytic and secretolytic effects. The antibacterial effect of the drug, due to the thymol component of the essential oil of thyme herb, has also been confirmed.

Pharmacokinetics. The thymol component of thyme essential oil is excreted mainly by the lungs. Flavonoids (e.g. apigenin, luteolin) of thyme herb are broken down by the intestinal flora and are well absorbed into the blood and excreted either unchanged or as metabolites, mainly by the kidneys.

Treatment of acute and inflammatory diseases of the respiratory tract, accompanied by cough with the formation of viscous sputum.

Adults and children over 12 years of age should take 1 tablet 3 times a day.

The tablets should be taken without chewing, with sufficient liquid (preferably a glass of water), before meals.

The duration of treatment depends on the course of the disease. Usually the course of treatment is 1 week. If prolonged treatment is necessary, the patient should consult a doctor. See also the information in the sections Features of use and side effects.

Increased individual sensitivity to the components of the drug, as well as other types of primroses or other medicinal plants of the Labiatae family, to birch, wormwood and celery.

Gastrointestinal disturbances, including cramps, nausea, vomiting, diarrhea, are uncommon. Hypersensitivity reactions, including difficulty breathing, skin rashes, itching, hives, swelling of the face, mouth and/or throat, are very rare.

If any adverse reactions occur, discontinue use of the drug and consult a doctor.

If an allergic reaction occurs, Bronchipret TP tablets should not be used again.

Due to the content of glucose and lactose, the drug should not be taken by patients with hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption.

If symptoms persist for more than 1 week or difficulty breathing, fever, purulent or bloody sputum occurs, the patient should immediately consult a doctor.

Patients with gastritis or stomach ulcers should not use Bronchipret TP film-coated tablets without consulting a doctor.

Note for diabetics. 1 tablet contains an average of 0.02 XE. The tablets do not contain gluten.

Use during pregnancy and breastfeeding

Pregnancy. Due to insufficient data on use, the drug should not be used during pregnancy and breastfeeding.

Fertility: There are no data on the effect of the drug on female reproductive capacity. No effect on fertility was observed in experimental studies.

Children: Due to insufficient safety studies, the drug should not be used in children under 12 years of age.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.

Not noted. Possible use in combination with antibacterial drugs.

Stomach upset, vomiting and diarrhea are possible. Treatment is symptomatic.

In the original packaging at a temperature not exceeding 25 °C.